Surface Plasmon Resonance (SPR) Spectrometry

Creative Biolabs has established an advanced surface plasmon resonance (SPR) technology platform with several services for drug discovery, including fragment-based screening, targets characterization, lead optimization, and any other services you required.

SPR biosensors have quickly turned into a standard technique within the biotechnology and pharmaceutical industries. This technique enables to be applied to identify the interactions of almost any molecular system. SPR is the oscillating movement of conduction electrons at the interface between a negative and positive permittivity material fuelled by incident light. Plasmon waves are subtle to the refractive index of the intermediary close the surface through which they pass. The two pivotal advantages of SPR technology are real-time analysis and no labeling necessities. The short of labeling decreases the time demanded to prepare samples for determination and eliminates the concern that a tag may influence the reaction. Real-time monitoring allows it feasible to extract particular information about binding events, containing the association and dissociation reaction kinetics. Creative Biolabs can provide unique SPR technology services for you with experts sophisticated in drug discovery.

Figure 1. Typical set-up for an SPR biosensor. (Cooper 2002)

Figure 2. SPR biosensor assays may be configured to monitor the interactions of different types of biological molecules. (Myszka and Rich, 2003)

Fragment-Based Screening

One method to perform biosensor technology in high throughput screening refers to the utilization of array-based biosensor technology. Scientists from Creative Biolabs use small molecule libraries micro-arrayed on SPR biosensor surfaces for fragment-based drug screening. Rather than screening numerous compounds against an immobilizing target, out team uses one target against thousands of compounds which spatially resolved on a surface. Structurally relative compounds are ranged within particular patterns on the chip, therefore a good deal of SAR information is obtained from the primary screen.

Targets and Compounds Characterization

Currently, various drugs that target membrane-bound proteins are under research or manufacture. SPR biosensors can offer a remarkable chance to study these classes of proteins in native lipid states. In addition, all-sided characterization of the interaction of compounds with a target protein is very crucial during the phases where hundreds of potential 'lead compounds' must be researched before succeeding optimization of selected leads. SPR technique offers an approach which enables the direct determination of the interactions between unlabeled compounds and the targets, thus providing an available way for compounds characterization.

Lead Optimization

A lead compound's pharmacokinetic and pharmacodynamic (PK/PD) characteristics are influenced by the compound-target binding rates (on- and off-rates). Kinetic evaluation of a lead using SPR guarantees selection of compounds on conditions that are related to target binding and target selectivity in vivo. Characterization of biotherapeutic candidates and label-free screening using SPR are able to adjust early in vitro ADME-indicating analyses, for instance, compound binding to multiple plasma proteins and binding to liposomes of different compositions.

Creative Biolabs provides other various drug discovery services. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Cooper MA (2002). “Optical biosensors in drug discovery”. Nature Reviews Drug Discovery 1(7), 515-528.
2. Myszka DG and Rich RL (2003). “SPR's high impact on drug discovery: Resolution, throughput, and versatility”. Drug Discovery World, 1-5.
3. Rich RL (2000). “Advances in surface plasmon resonance biosensor analysis”. Current opinion in biotechnology 11(1), 54-61.

For Research Use Only.